Kronos Bio is focused on developing small molecule therapeutics that target deregulated transcription. Credit: Pickadook /Shutterstock. Kronos Bio has announced the appointment of Deborah Knobelman as ...

Kronos Bio has announced the appointment of Deborah Knobelman as president and interim chief executive officer, effective from 3 December 2024. Dr Knobelman will also become principal executive and ...

The latest update is out from Kronos Bio ( (KRON)). Kronos Bio, Inc. is undergoing a significant transformation with an 83% workforce reduction aimed at strategic cost containment by December 31, 2024 ...

On the heels Kronos Bio’s decision to can its last remaining clinical asset earlier this month, the company said it would roll out “significant expense reduction strategies” to buy itself more time.

Kronos Bio has made its second round of layoffs in five months, with another fifth of the biotech’s workforce heading to the exits as the company focuses on a CDK9 inhibitor. Laying off 21% of staff ...

Kronos Bio (NASDAQ:KRON) said it was laying off 21% of its workforce as part of a restructuring effort that will extend its cash runway into the second half of 2026. The company intends to focus its ...

Ultimate Kronos Group, one of the largest human resources companies, disclosed a crippling ransomware attack on Monday, impacting payroll systems for a number of workers. After noticing “unusual ...

Kronos Private Cloud was the target of a ransomware attack earlier this week. The attack impacted several Kronos services, including workforce management tools like time cards and payroll. As of ...